Continuous subcutaneous levodopa/carbidopa infusion with ND0612 for patients with Parkinson’s disease and motor fluctuations: Results from the Phase 3 randomized, active-controlled BouNDless study
Objective: Determine the efficacy, safety, and tolerability of ND0612 versus oral immediate-release levodopa/carbidopa (IR-LD/CD) in people with Parkinson’s disease (PwP) experiencing motor fluctuations. Background: ND0612…Dietary protein redistribution influences the efficacy of levodopa/carbidopa intestinal gel (LCIG) infusion
Objective: To compare levodopa/carbidopa intestinal gel (LCIG) with equally distributed dietary protein (Diet_EDP) versus restricted to twice daily (Diet_RP) and Mediterranean diet (Diet_M). Background: Levodopa…Marked reduction of energy supply due to levodopa treatment in patients with Parkinson’s disease and healthy controls
Objective: To investigate the influence of a standardized, placebo-controlled administration of levodopa on cerebral bioenergetics in patients with Parkinson’s disease (PwPD) and healthy controls (HCs).…Stability and predictability of motor symptom control in patients with advanced Parkinson’s disease (aPD) receiving continuous subcutaneous foslevodopa/foscarbidopa (LDP/CDP)
Objective: To evaluate temporal changes in motor states (OFF and ON without troublesome dyskinesia [TD; good ON]) throughout the waking day in patients with aPD…Ocular microtremor in Parkinson’s Disease: Protocol for an observational pilot study
Objective: This study aims to examine OMT in people with PD (PwPD) compared to healthy older adults. Identifying OMT as a PD biomarker could better…Effectiveness of use of Pictographs on Levodopa packaging to ensure awareness of Levodopa/Carbidopa spacing with meals in patients of Idiopathic Parkinson’s disease.
Objective: Food interferes with gastrointestinal absorption of levodopa which requires spacing with meals. This study aimed to evaluate the effect pictographs on Levodopa packaging Fig 1 on increasing patient…Use of concomitant medications before and after treatment with levodopa/carbidopa intestinal gel in patients with advanced Parkinson’s disease: summary of phase 3 and real-world studies
Objective: Evaluate the use of concomitant Parkinson’s disease (PD) medications before and after treatment with levodopa/carbidopa intestinal gel (LCIG) using data from phase 3 clinical…ON/OFF Non-Motor Evaluation: A New Way to Evaluate Non-Motor Fluctuations in Parkinson’s Disease
Objective: To validate an auto-questionnaire allowing a real time evaluation of the severity of NMF in PD. Background: Non-motor fluctuations (NMF) in Parkinson's disease (PD)…Improvement of nocturia symptoms and associated quality of life in patients with Parkinson’s disease treated with foslevodopa/foscarbidopa: results from 2 phase 3 trials
Objective: To assess nocturia over time and its correlation with quality of life (QoL) in patients with Parkinson’s disease (PD) treated with foslevodopa/foscarbidopa (LDP/CDP). Background:…Randomized Controlled Trial comparing continuous intrajejunal levodopa infusion and deep brain stimulation for Parkinson’s disease. Cost-effectiveness and cost-utility outcomes of the INVEST study
Objective: To determine the costs of continuous intrajejunal levodopa infusion (CILI) and deep brain stimulation (DBS) for Parkinson’s disease (PD), and to study the cost-effectiveness…
- « Previous Page
- 1
- …
- 14
- 15
- 16
- 17
- 18
- …
- 62
- Next Page »